PLCG1 expression was reduced in MDS with a high blast percentage (5% or more) compared to those with a low blast percentage (less than 5%), which suggests that reduced PLCG1 has a role in the progression of MDS. The gene discussed is PLCG1; the disease is myelodysplastic syndrome.